The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Safety and tolerability of subcutaneous sarilumab and intravenous tocilizumab in patients with rheumatoid arthritis
Abstract
Objective: Safety and efficacy of mAbs blocking the IL-6 receptor have been established in RA. This is the first analysis examining safety and tolerability of sarilumab and tocilizumab administered as single or multiple doses in patients with RA within the same study. Methods: In ASCERTAIN, patients were randomized 1: 1: 2 to 24 weeks’ double-blind sarilumab 150 or 200 mg every 2 weeks s.c. or tocilizumab 4 mg/kg every 4 weeks i.v., increased to 8 mg/kg if clinically indicated. In Study 1309, patients were randomized 1: 1: 1: 1 to single-dose open-label sarilumab 150 or 200 mg s.c. or tocilizumab 4 or 8 mg/kg i.v. Results: In ASCERTAIN, incidence of treatment-emergent adverse events was similar between sarilumab and tocilizumab. The most common treatment-emergent adverse events were the following: sarilumab: neutropenia [6 patients (12.2%) in the 150 mg group and 8 (15.7%) in the 200 mg group], nasopharyngitis [6 (12.2%) and 3 (5.9%)], and injection-site erythema [4 (8.2%) and 4 (7.8%)]; tocilizumab: accidental overdose [9 (8.8%)], upper respiratory tract infection [7 (6.9%)] and nausea [7 (6.9%)]. Laboratory changes in both studies included decreased neutrophils and platelets and increased transaminases and lipids. In Study 1309, incidence of absolute neutrophil count <1.0 giga/l was similar between sarilumab and tocilizumab, and occurred more frequently in the higher dose groups. No association between decrease in absolute neutrophil count and increased incidence of infection was observed in either study. Conclusion: No clinically meaningful differences in treatment-emergent adverse events were observed between sarilumab and tocilizumab. Laboratory changes with sarilumab were within the same range as those with tocilizumab. Trial registration numbers: ASCERTAIN (NCT01768572); Study 1309 (NCT02097524).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In the ASCERTAIN study (NCT01768572), clinically meaningful adverse events, including abnormal laboratory tests, were comparable across the treatment groups”
From Targeting Interleukin-6 Signaling in Clinic (2019) · cites this paper as Emery et al., 2018
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Genovese, M. C., McKay, J. D., Nasonov, E. L., Mysler, E. F., da Silva, N. A., Alecock, E., Woodworth, T., & Gomez‐Reino, J. J. (2008) · Arthritis & Rheumatism · doi:10.1002/art.23940 · Cited by 855
Research works printed but not linked: 11
- Choy, 2012, Understanding the dynamics: pathways involved in the pathogenesis of rheumatoid arthritis, Rheumatology (Oxford), 51, v3, 10.1093/rheumatology/kes113 · DOI · Paper page
- Srirangan, 2010, The role of interleukin 6 in the pathophysiology of rheumatoid arthritis, Ther Adv Musculoskelet Dis, 2, 247, 10.1177/1759720X10378372 · DOI · Paper page
- Yoshida, 2014, Interleukin 6 and rheumatoid arthritis, Biomed Res Int, 2014, 1, 10.1155/2014/698313 · DOI · Paper page
- Smolen, 2014, Sirukumab, a human anti-interleukin-6 monoclonal antibody: a randomised, 2-part (proof-of-concept and dose-finding), phase II study in patients with active rheumatoid arthritis despite methotrexate therapy, Ann Rheum Dis, 73, 1616, 10.1136/annrheumdis-2013-205137 · DOI · Paper page
- Weinblatt, 2015, The efficacy and safety of subcutaneous clazakizumab in patients with moderate-to-severe rheumatoid arthritis and an inadequate response to methotrexate: results from a multinational, phase IIb, randomized, double-blind, placebo/active-controlled, dose-ranging study, Arthritis Rheumatol, 67, 2591, 10.1002/art.39249 · DOI · Paper page
- Dörner, 2017, FRI0239 Results of a phase 2b study of vobarilizumab, an anti-interleukin-6 receptor nanobody, as monotherapy in patients with moderate to severe rheumatoid arthritis, Ann Rheum Dis, 76, 575, 10.1136/annrheumdis-2017-eular.3746 · doi:10.1136/annrheumdis-2017-eular.3746
- Genovese, 2015, Sarilumab plus methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate: results of a Phase III study, Arthritis Rheum, 67, 1424, 10.1002/art.39093 · DOI · Paper page
- Aletaha, 2010, 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative, Ann Rheum Dis, 69, 1580, 10.1136/ard.2010.138461 · DOI · Paper page
- Hochberg, 1992, The American College of Rheumatology 1991 revised criteria for the classification of global functional status in rheumatoid arthritis, Arthritis Rheum, 35, 498, 10.1002/art.1780350502 · DOI · Paper page
- Summers, 2010, Neutrophil kinetics in health and disease, Trends Immunol, 31, 318, 10.1016/j.it.2010.05.006 · DOI · Paper page
- Gibiansky, 2012, Linking interleukin-6 receptor blockade with tocilizumab and its hematological effects using a modeling approach, J Pharmacokinet Pharmacodyn, 39, 5, 10.1007/s10928-011-9227-z · DOI
Cited by
Update on the Pathomechanism, Diagnosis, and Treatment Options for Rheumatoid Arthritis
Lin, Y.-J., Anzaghe, M., & Schülke, S. (2020) · Cells · doi:10.3390/cells9040880 · Cited by 932
Self-citationTargeting Interleukin-6 Signaling in Clinic
Kang, S., Tanaka, T., Narazaki, M., & Kishimoto, T. (2019) · Immunity · doi:10.1016/j.immuni.2019.03.026 · Cited by 904
Translating IL-6 biology into effective treatments
Choy, E. H., De Benedetti, F., Takeuchi, T., Hashizume, M., John, M. R., & Kishimoto, T. (2020) · Nature Reviews Rheumatology · doi:10.1038/s41584-020-0419-z · Cited by 668
Sepriano, A., Kerschbaumer, A., Smolen, J. S., van der Heijde, D., Dougados, M., van Vollenhoven, R., McInnes, I. B., Bijlsma, J. W., Burmester, G. R., de Wit, M., et al. (2020) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2019-216653 · Cited by 275
Burmester, G. R., Lin, Y., Patel, R., van Adelsberg, J., Mangan, E. K., Graham, N. M. H., van Hoogstraten, H., Bauer, D., Ignacio Vargas, J., & Lee, E. B. (2017) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2016-210310 · Cited by 272
Self-citation
Metadata
- Authors
- Emery, P., Rondon, J., Parrino, J., Lin, Y., Pena-Rossi, C., van Hoogstraten, H., Graham, N. M. H., Liu, N., Paccaly, A., Wu, R., & Spindler, A.
- Affiliations
- Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals Trust, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK
- Arthritis and Rheumatic Diseases of South Florida, Pembroke Pines, FL, USA
- Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA
- Sanofi Genzyme, Bridgewater, NJ, USA
- Rheumatology, Universidad Nacional de Tucumán, Tucumán, Argentina
- Venue
- Rheumatology
- Publisher
- Oxford University Press (OUP)
- Published
- 2018-12-19
- Volume
- 58
- Issue
- 5
- Pages
- 849-858
- ISSN
- 1462-0324
- 1462-0332
- Cited by
- 95
- References
- 1
- Language
- en
- Funders
- Sanofi Genzyme
- Regeneron Pharmaceuticals, Inc
- Abbott
- Eli Lilly
- Sanofi
- Regeneron Pharmaceuticals
- Inc.
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Safety and tolerability of subcutaneous sarilumab and intravenous tocilizumab in patients with rheumatoid arthritis. https://app.cochat.ai/papers/10.1093/rheumatology/key361
- The paper
- Emery, P., Rondon, J., Parrino, J., Lin, Y., Pena-Rossi, C., van Hoogstraten, H., Graham, N. M. H., Liu, N., Paccaly, A., Wu, R., & Spindler, A. (2019). Safety and tolerability of subcutaneous sarilumab and intravenous tocilizumab in patients with rheumatoid arthritis. Rheumatology. https://doi.org/10.1093/rheumatology/key361
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.